• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Coenzyme A Activates TLR4 To Boost Macrophage Alternative Activation

by
November 14, 2026
in Biology
Reading Time: 6 mins read
0
Coenzyme A Activates TLR4 To Boost Macrophage Alternative Activation

Coenzyme A Activates TLR4 To Boost Macrophage Alternative Activation

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at the University of California, Los Angeles, have identified a previously unknown immunological function for coenzyme A (CoA), a ubiquitous metabolic cofactor essential for cellular energy production. In a study published in EMBO Reports, the team demonstrated that exogenous CoA acts as a weak agonist for Toll-like receptor 4 (TLR4), a pattern recognition receptor typically associated with detecting pathogen-derived molecules. This activation triggers MyD88-linked signaling, which unexpectedly enhances the alternative activation of macrophages, a state associated with tissue repair and the resolution of inflammation.

The discovery resolves a mechanistic puzzle from prior research in the same laboratory. Previous work had shown that high concentrations of the drug etomoxir, a carnitine palmitoyltransferase-1 inhibitor, blocked the macrophage response to interleukin-4 (IL-4). The team had observed that adding exogenous CoA restored both intracellular CoA levels and the expression of IL-4-linked cell surface markers. However, the specific mechanism by which CoA instructed macrophage activation remained undefined, leading the current study to investigate whether the effect was metabolic or signaling-based.

To test the metabolic hypothesis, the researchers examined whether CoA enhanced alternative macrophage activation by increasing flux through metabolic pathways linked to the IL-4 response. Using mouse bone marrow-derived macrophages (BMDMs), they measured respiratory capacity, glycolysis, and de novo lipid synthesis. Contrary to expectations, the addition of CoA did not augment these metabolic hallmarks. In fact, CoA provision limited the glycolytic rate and maximal respiratory capacity of alternatively activated macrophages, suggesting that the enhancement of the IL-4 response was independent of metabolic reprogramming.

The team further investigated whether changes in intracellular CoA levels were sufficient to alter macrophage polarization. They utilized two compounds with opposing effects on CoA homeostasis: cyclopropane carboxylic acid (CPCA) to decrease free CoA levels and PZ-2891, a pantothenate kinase activator, to increase CoA biosynthesis. Despite significant shifts in steady-state intracellular CoA and acetyl-CoA levels, neither compound impacted the gene expression or cell surface markers associated with alternative activation. This indicated that the pro-inflammatory and pro-reparative effects of exogenous CoA were not mediated by changes in the intracellular CoA pool.

Transcriptomic analysis revealed that CoA induced a pro-inflammatory response in macrophages alongside its ability to enhance alternative activation. Bulk RNA sequencing showed that CoA increased the expression of genes associated with classical activation, including Il1b, Tnf, Irg1, and Nos2. These genes are linked to the TLR adapter protein MyD88. The team also observed a roughly ten-fold increase in itaconate synthesis, an antimicrobial metabolite, upon CoA provision. This dual effect suggested that CoA might be acting as a damage-associated molecular pattern (DAMP) that primes macrophages for both inflammation and resolution.

To identify the specific receptor involved, the researchers used HEK-Blue reporter cells expressing human TLR2, TLR4, or TLR7. CoA activated the TLR4 reporter cells but had no effect on TLR2 or TLR7. Interpolation of a standard curve using lipopolysaccharide (LPS), the canonical TLR4 ligand, showed that 1 mM CoA had a comparable effect to 0.1 ng/mL LPS, characterizing it as a relatively weak TLR4 agonist. Genetic validation using BMDMs from Tlr4 knockout mice confirmed that CoA failed to increase pro-inflammatory gene expression or itaconate production in the absence of TLR4.

The study further demonstrated that MyD88-linked signaling is the primary pathway mediating the enhanced IL-4 response. Co-treatment with other MyD88-dependent TLR agonists, such as Pam3CSK4 (TLR2) and imiquimod (TLR7), also increased the population of CD206+ and CD301+ macrophages. In contrast, the TRIF-linked TLR3 agonist Poly (I:C) decreased this population. In MyD88 knockout macrophages, the effect of low-dose LPS and Pam3CSK4 on IL-4-associated markers was lost, confirming the necessity of the MyD88 adapter for this cooperative effect.

In vivo experiments confirmed that CoA enhances alternative macrophage activation in living organisms. Mice treated intraperitoneally with CoA prior to IL-4 complex administration showed an increased frequency of CD206+ and CD71+ peritoneal macrophages. Additionally, the team observed that CoA induced a pro-inflammatory response in mice, increasing the abundance of IL-1β, TNF-α, IL-6, and CXCL1 in the peritoneal lavage fluid. These findings support the model that CoA acts as an endogenous DAMP capable of modulating the innate immune response in situ.

Mechanistic studies using ATAC-seq revealed how MyD88 signaling enhances the IL-4 response at the epigenetic level. The analysis identified 10,878 genomic regions with increased accessibility following IL-4 stimulation. Co-treatment with the MyD88 agonist Pam3CSK4 further increased the accessibility of over 30% of these regions. Motif analysis indicated that these regions were enriched for STAT6 and Jun/AP-1 binding motifs. Specifically, the promoter regions of IL-4 target genes Chil4 and Ccl8 became more accessible upon Pam3CSK4 exposure, suggesting that Jun/AP-1 family transcription factors may mediate the synergy between MyD88 signaling and IL-4 responsiveness.

The researchers also addressed potential confounding factors, such as endotoxin contamination or impurities in the CoA preparation. A Limulus test confirmed that the yeast-derived CoA was free of endotoxin. Furthermore, synthetic CoA with higher purity elicited a more potent pro-inflammatory response than the yeast-derived form, yet both forms similarly enhanced IL-4-dependent cell surface markers. This indicates that the CoA molecule itself, rather than a contaminant, is responsible for the observed immunological effects.

The study highlights the plasticity of macrophage polarization, demonstrating that pro-inflammatory MyD88-linked signaling can support alternative activation and the resolution of inflammation. This challenges the traditional view of classical and alternative activation as mutually exclusive states. The findings suggest that metabolic cofactors can serve as extrinsic signals that shape the innate immune response, with potential implications for understanding sterile inflammation and tissue repair processes.

Limitations of the study include the use of relatively high concentrations of CoA in vitro, although the effect was observed at concentrations as low as 62.5 µM. The team noted that while intracellular CoA levels can reach over 100 µM in the cytosol, the physiological relevance of extracellular CoA as a DAMP requires further investigation. The study primarily used mouse models, though human monocyte-derived macrophages also showed enhanced IL-4-linked gene expression in response to CoA, suggesting the mechanism may be conserved across species.

These results provide a new framework for understanding how metabolic cofactors influence immune function. By identifying CoA as a TLR4 agonist, the study bridges the gap between metabolism and innate immunity. The identification of Jun/AP-1 as a candidate mediator offers a target for future research into the epigenetic regulation of macrophage polarization. The work underscores the complexity of macrophage responses to endogenous signals and the importance of considering both pro-inflammatory and anti-inflammatory pathways in the context of tissue homeostasis.

Beyond tracking surface markers, the researchers verified the functional consequences of coenzyme A supplementation on macrophage endocytosis. High-content imaging showed that bone marrow-derived macrophages treated with coenzyme A and interleukin-4 exhibited significantly increased internalization of FITC-dextran, a fluorescent tracer recognized by the CD206 mannose receptor. The investigators also examined whether the cofactor operated by elevating interleukin-4 receptor expression through the transcription factor STAT3. When cells were exposed to the pharmacological STAT3 inhibitor napabucasin, overall interleukin-4 responsiveness diminished, yet coenzyme A retained its ability to augment Ccl8 transcript levels and expand the percentage of CD206 and CD301 double-positive macrophages, demonstrating that the amplification operates independently of STAT3 signaling.

To determine if MyD88-mediated priming alters physiological tissue outcomes in vivo, the team evaluated a syngeneic B16-F10 melanoma model. Alternative macrophage activation is known to promote tumor growth in this setting. Macrophages stimulated in culture with interleukin-4 alongside the MyD88-activating toll-like receptor 2 agonist Pam3CSK4 were mixed in equal parts with B16-F10 melanoma cells and injected subcutaneously into the flanks of male C57BL/6 mice. After twenty days, excised tumors were substantially heavier than those derived from mixtures containing macrophages primed with interleukin-4 alone. This demonstrated that MyD88 agonism functionally augments macrophage programs that sustain tissue remodeling and cell proliferation within an active tissue microenvironment.

The investigators also tested whether this cooperative mechanism extends to human immune cells using peripheral blood monocyte-derived macrophages. Providing coenzyme A alongside interleukin-4 strongly upregulated human genes characteristic of alternative activation, including CCL17, TGM2, PDCD1LG2, and IRF4. Interestingly, while the response to classical ligands like low-dose endotoxin strictly required MyD88, coenzyme A and the agonist imiquimod retained partial activity in MyD88-deficient cells. Because coenzyme A structurally comprises an adenosine diphosphate moiety joined to a phosphopantetheine arm, the researchers noted that its adenine-like structure might permit secondary interactions with distinct surface purinergic receptors to reinforce alternative activation pathways.

These findings provide a mechanistic framework for understanding how metabolic cofactors function as alarm signals during sterile trauma. Intracellular coenzyme A reaches approximately 100 micromolar in the cytosol and up to 5 millimolar inside the mitochondrial matrix. Following acute cell lysis or tissue trauma, uncompartmentalized coenzyme A can accumulate locally at concentrations sufficient to engage Toll-like receptor 4, particularly in poorly vascularized beds or tissues with dense metabolic turnover such as the liver. By acting as an extrinsic danger-associated molecular pattern, released coenzyme A recruits early defense mechanisms while simultaneously priming surrounding macrophages to resolve inflammation and coordinate subsequent tissue repair.

Subject of Research: Immunology and Macrophage Metabolism

Article Title: Coenzyme A activates TLR4 and enhances alternative macrophage activation in line with MyD88 agonism

Article References: Jones, A. E., Rios, A., Ibrahimovic, N., Ball, A. B., Chavez, C., Bayley, N. A., Falta, N. A., Mekkittikul, M., Carrillo, C., Hsieh, W. Y., Sammarco, A., Reyes, A. B., Cortez, A. A., Graeber, T. G., Watson, R. L., Hoffmann, A., Bensinger, S. J., & Divakaruni, A. S. (2026). Coenzyme A activates TLR4 and enhances alternative macrophage activation in line with MyD88 agonism. EMBO Reports, 27(20), 5927-5952. https://doi.org/10.1038/s44319-026-00925-y

Image Credits: AI Generated

DOI: 10.1038/s44319-026-00925-y

Keywords: Coenzyme A, TLR4, Macrophage Polarization, MyD88 Signaling, Alternative Activation, Interleukin-4, DAMPs, EMBO Reports, Innate Immunity, Chromatin Accessibility, ATAC-seq, Inflammation Resolution, Metabolic Cofactors, UCLA Research, Coenzyme

News Source: Drew Townsend. (November 14, 2026). Coenzyme A Activates TLR4 To Boost Macrophage Alternative Activation. Scienmag.

Tags: Alternative ActivationATAC-seqChromatin accessibilityCoenzymecoenzyme ADAMPsEMBO Reportsinflammation resolutionInnate immunityinterleukin-4Macrophage polarizationmetabolic cofactorsMyD88 signalingTLR4UCLA Research
Share12Tweet7Share2ShareShareShare1

Related Posts

Fermented Camel Milk Peptides Show Potential to Combat Inflammation and Diabetes

Fermented Camel Milk Peptides Show Potential to Combat Inflammation and Diabetes

November 16, 2026
McDag Indexes Maximal Common Subsequences Across Multiple Genomic Sequences in Minutes

McDag Indexes Maximal Common Subsequences Across Multiple Genomic Sequences in Minutes

November 16, 2026

Protein IGF2BP2 Controls Tumor Cell Metabolism Through Mitochondrial Transporters and Lipids

November 16, 2026

Lipotoxicity Triggers Organelle Dysfunction and Follicular Arrest in Metabolic PCOS

November 16, 2026

POPULAR NEWS

  • Repetitive Behaviors Link Autistic Traits Between Children and Parents in Family Study

    Repetitive Behaviors Link Autistic Traits Between Children and Parents in Family Study

    29 shares
    Share 12 Tweet 7
  • Urinary Calprotectin Outperforms Novel Biomarkers in Pediatric Acute Kidney Injury Differentiation

    29 shares
    Share 12 Tweet 7
  • Twelve Percent of Children with Neuroblastoma Experience Initial Musculoskeletal Misdiagnoses

    29 shares
    Share 12 Tweet 7
  • Tunable Plasma Photonic Crystals Enable Dynamic Control Over Topology and Electromagnetism

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Computational Modeling Implicates NMDA Receptor Hypofunction in 22q11.2 Deletion Syndrome

Prenatal Dexamethasone Exposure Impairs Hippocampal Neurogenesis and Promotes Depression in Mice

Elevated Urine Albumin-to-Creatinine Ratio Linked to Incident Depression and Anxiety

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.